A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma
brief summary
The primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma. The study also evaluates the safety and tolerability of the combination therapy.
detailed description
This multicenter, open-label, adaptive Phase II study evaluates the combination of HF1K16 and Bevacizumab in recurrent or progressive glioma. HF1K16 combines a lipid bilayer structure with all-trans retinoic acid (ATRA). In glioma patients, myeloid-derived suppressor cells (MDSCs) typically accumulate and exert strong immunosuppressive activity. HF1K16 is designed to induce immature MDSCs to differentiate into mature, active immune cells, thereby reversing immune suppression in the tumor microenvironment. The combination of HF1K16 and Bevacizumab is expected to achieve a synergistic anti-tumor effect by simultaneously inhibiting angiogenesis and remodeling the immunosuppressive tumor microenvironment to maximize efficacy.
official title
A Multicenter, Open-Label, Adaptive Phase Ⅱ Clinical Study of HF1K16 Combined With Bevacizumab in Recurrent or Progressive Glioma